Reactions Weekly

, Volume 1212, Issue 1, pp 2–2 | Cite as

BioAlliance Pharma has suspended the doxorubicin Transdrug® phase II/III trial

Media release


Public Health Adverse Event Doxorubicin Initial Data Clinical Benefit 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    BioAlliance Pharma SA.BioAlliance Pharma Suspends the Phase II/III Trial of Doxorubicin Transdrug (Rm) In Primary Liver Cancer, Following Advice from the Drug Safety Monitoring Board and the Steering Committee. Media Release: 16 Jul 2008. Available from: URL:

Copyright information

© Adis International limited or Adis Data Information BV 2008

Personalised recommendations